Results 211 to 220 of about 171,263 (267)

Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential. [PDF]

Biomedicines
Sah AK, Das J, Umarovich AI, Agarwal S, Prabhakar PK, Vashishtha A, Elshaikh RH, Choudhary RK, Alfeel AH.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Preclinical evaluation of UC781 microbicide vaginal drug delivery

Drug Delivery and Translational Research, 2011
UC781 is a potent nonnucleoside reverse transcriptase inhibitor being investigated as a potential microbicide to prevent transmission of HIV-1 both vaginally and rectally. This study was designed to investigate the in vitro drug release, in vitro permeability/safety, and in vivo pharmacokinetics in rabbits of a vaginal gel prepared with micronized or ...
Meredith R, Clark, Timothy J, McCormick, Gustavo F, Doncel, David R, Friend   +3 more
openaire   +2 more sources

Bupropion-induced convulsions: Preclinical evaluation of antiepileptic drugs

Epilepsy Research, 2005
Bupropion, a unique, non-nicotine smoking cessation aid and an effective antidepressant, is well known to produce seizures following overdosing in humans. However, the experimental background for the usefulness of antiepileptic drugs in the protection against bupropion-induced convulsions has not been established yet.
Piotr, Tutka, Tomasz, Mróz, Katarzyna, Klucha, Małgorzata, Piekarczyk, Marian, Wielosz   +4 more
openaire   +2 more sources

Evaluation of Nanoparticle Drug-Delivery Systems used in Preclinical Studies

Therapeutic Delivery, 2021
Multifunctional nanoparticles have been identified as a promising drug-delivery system for sustainable drug release. The structural and size tunability and disease-targeting ability of nanoparticles have made them more suitable for multiple drug loading and delivery, thereby enhancing therapeutic results through synergistic effects.
Nagaraja Sreeharsha, Nataraj Chitrapriya, Yoon Jung Jang, Vanaja Kenchappa   +3 more
openaire   +2 more sources

Preclinical evaluation of behavioral deficits following hypnotic drug treatment

Pharmacology Biochemistry and Behavior, 1986
Most hypnotic medications result in performance decrements, or "hangover effects," the morning after bedtime ingestion. However, the severity of hangover effects with new compounds is difficult to predict prior to clinical trials. This paper describes a preclinical procedure that is predictive of human hangover effects following bedtime ingestion of ...
J M, Halperin, J, Canon, L C, Iorio
openaire   +2 more sources

Technological Advances in Preclinical Drug Evaluation: The Role of -Omics Methods

Current Medicinal Chemistry, 2020
Preclinical drug development is an essential step in the drug development process where the evaluation of new chemical entities occurs. In particular, preclinical drug development phases include deep analysis of drug candidates’ interactions with biomolecules/targets, their safety, toxicity, pharmacokinetics, metabolism by use of assays in vitro and ...
Kraljević Pavelić, Sandra, Markova-Car, Elitza, Klobučar, Marko, Sappe, Lana, Spaventi, Radan   +4 more
openaire   +4 more sources

NCI Specialized Procedures in Preclinical Drug Evaluations

2004
Agents now come to the U.S. National Cancer Institute (NCI) from many sources for preclinical evaluation and/or potential development (1). In most cases, experimental agents have limited antiproliferative data against a broad spectrum of human cancers, and these agents usually are then tested in the NCI’ s in vitro anticancer drug screen. Data from the
Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, Sherman F. Stinson   +4 more
openaire   +1 more source

EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms

Radiotherapy and Oncology, 2007
Preclinical and clinical results indicate that the EGFR can mediate radioresistance in different solid human tumours. Combination of radiotherapy and EGFR inhibitors can improve local tumour control compared to irradiation alone and has been introduced into clinical radiotherapy practice.
Michael, Baumann, Mechthild, Krause, Ekkehard, Dikomey, Klaus, Dittmann, Wolfgang, Dörr, Ulla, Kasten-Pisula, H Peter, Rodemann   +6 more
openaire   +2 more sources

Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs

2005
Type I and II DNA topoisomerases are the targets for numerous clinically efficacious antitumor agents. Over the last decade, considerable effort has been expended in developing camptothecin (CPT) derivatives that selectively target DNA topoisomerase I (TOP-I) (1).
Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, Peter J. Houghton   +3 more
openaire   +1 more source

Preclinical Drug Evaluation with Human Melanoma Xenografts

1988
In 1974 there was an increasing awareness at the National Cancer Institute of the U.S.A. that important drugs might have been missed by the conventional murine tumor screening system then employed. Differences in biochemistry and cell biology of murine vs. human tumors were increasingly well understood.
openaire   +1 more source